Tumour markers: An overview

Indian Journal of Clinical Biochemistry

Volumn 22, Issue 2, 2007, Pages 17-31

  Malati, T ^a  

^a NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Cancer progression; Carcinogenesis; Malignancy; Prognostic value; Tumor markers

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ALKALINE PHOSPHATASE PLACENTA ISOENZYME; ALPHA FETOPROTEIN; AMYLASE; BETA 2 MICROGLOBULIN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CA 50 ANTIGEN; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN BETA SUBUNIT; DNA NUCLEOTIDYLEXOTRANSFERASE; EPITOPE; ESTROGEN RECEPTOR; FERRITIN; FIBRINOGEN DEGRADATION PRODUCT; GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCOSYLTRANSFERASE; LYSOZYME; NEURON SPECIFIC ENOLASE; ONCOFETAL ANTIGEN; PARAPROTEIN; PLACENTA LACTOGEN; POLYAMINE; PROGESTERONE RECEPTOR; PROSTATE SPECIFIC ANTIGEN; PROTEIN S 100; TUMOR ANTIGEN; TUMOR MARKER;

ACCURACY; AMINO ACID SEQUENCE; ARTICLE; BILIARY TRACT CANCER; BREAST CANCER; CANCER GROWTH; CANCER STAGING; CANCER THERAPY; CARCINOGENESIS; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGUS CANCER; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; GENE MUTATION; GYNECOLOGIC CANCER; HUMAN; LIVER CANCER; LUNG CANCER; METASTASIS; ONCOGENE; OUTCOME ASSESSMENT; PANCREAS CANCER; PROGNOSIS; PROTEIN BLOOD LEVEL; RECEPTOR BINDING; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; TUMOR CELL; TUMOR SUPPRESSOR GENE;

EID: 36849050932     PISSN: 09701915     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02913308     Document Type: Article

References (105)

1. Chu TM. Biochemical markers for human cancer, In Morphological Tumors Markers, general aspects and diagnostic relevance. Seifert G (ed.) Springer Verlag 1987; p:19-42.
2. Harnden D G. Human Tumor Markers: Biological Basis and Clinical Relevance. J Roy Soc Med 1985; 78:1071-2.
3. Virji MA, Mercer DW, Herberman RB. Tumor Markers and their measurements. Pathol Res Pract 1988; 183:95-9.
4. Bates SE, Longo DL. Use of serum tumor markers in cancer diagnosis and management. Semin. Oncol 1987; 14:102-38.
5. Paterson AJ, Schlom J, Seares HF. A radioimmunoassay for the detection of a human tumor-associated glycoprotein (TAG 72) using monoclonal antibody B 72-3. Int J Cancer 1986; 37:659-66.
6. Esteva FJ, Hortobagyi GN. Prognostic molecular markers in early breast cancer. Breast Cancer Res 2004; 6:109-18.
7. Fitzgeralk MG, MacDonald DJ, Krainer MG. BRCA1 mutations in Jewish women with early onset breast cancer. N Engl J Med 1996; 334:143-9.
8. Del Villano BC, Brennan S, Brock P. Radioimmunometric assay for monoclonal antibody-defined tumor marker CA 19-9. Clin Hem 1983; 29:549-52.
9. Bhattacharya S, Siegel ER, Petersen GM, Chari ST, Suva L, Haun RS. Diagnosis of Pancreatic Cancer Using Serum Proteomic Profiling. Neoplasia 2004; 6:674-86.
10. Paterson AJ, Schlom J, Seares HF. A radioimmunoassay for the detection of a human tumor-associated glycoprotein (TAG 72) using monoclonal antibody B 72-3. Int J Cancer 1986; 37:659-66.
11. William MS, Richard G, Kimberly KA, Jerry G, Scott HK, William FS, Philip PT. Comparison of the Sensitivity and Specificity of the CA 19-9 and Carcinoembryonic Antigen assays in detecting cancer of the Pancreas. Gastroenterology 1986; 90:343-9.
12. Kurman RJ, Norris HJ. Endodermal sinus tumor of the ovary : A clinical and pathological analysis of 71 cases. Cancer 1976; 38:2404-19.
13. Saraswathi A, Raghunadharao D, Malati T. Cancer antigen CA 125 - A current marker for ovarian carcinoma (current diagnostics). Clin Proc NIMS 1994; 9:57-8.
14. Saraswathi A, Malati T. Superiority of CA 125 over CA 19-9 and CEA for epithelial ovarian malignancies. Ind J Clin Biochem 1995; 10:23-8.
15. Fanning J, Walker RLA, Shah NR. Mixed germ cell tumor of the ovary with pure choriocarcinoma metastasis. Obstet Gynecol 1986; 64-5.
16. Alpert E, Doysdale JW, Isselbacher KJ. Human alphafetoprotein: isolation, characterisation and demonstration of microheterogeneity. J Biol Chem 1972; 247:3792-8.
17. Yamashita K, Hitoi A, Tsuchida Y. Sugar chain of alphafetoprotein producing human yolk sac tumor. Cancer Res 1983; 43:4691-5.
18. Malati T, Vidya Rani G, Fatima T, Sundari Krishna PT, Ramaswamy S. Maternal serum alphafetoprotein in normal and high-risk pregnancy with a history of repeated abortions. Asian Journal of Clinical Sciences 1986; 6:140-44.
19. Fatima T, Malati T, Seeta T. Repeated Anencephaly and XO/ XX mosaicism in the mother. Human Genetics 1982; 62:289.
20. Malati T. Alpha fetoprotein in pregnant mothers with reproductive history of Neural tube defects: study of 50 cases. Society of biological chemists India annual conference (abstract) 1984.
21. Malati T, Saraswathi A, Yadagiri B, Kumar A, Dixit V K. Alpha-fetoprotein in liver disorders. J Int Med Acad Sci 1995; 8:87-90.
22. Buamah PK, Gibb I, Bates G. Serum alphafetoprotein heterogeneity as a means of differentiation between primary hepatocellular carcinoma and hepatic secondaries. Clin Chem Acta 1984; 139:313-6.
23. Talerman A, Haije WG, Baggerman L. Serum Alphafetoprotein (AFP) in patients with germ cell tumors of the gonads and etragonadal sites. Correlation between endodermal sinus (Yolk sac) tumors and raised serum AFP. Cancer1980; 46:380-85.
24. Kawai M, Furuhashi Y, Kano T. Alphafetoprotein in malignant germ cell tumors of the ovary. Gynecol Oncol 1990; 39:160-66.
25. Malati T, Saraswathi A, Vittal PV, Ananth Reddi P. Elevated serum AFP in a case of endodermal sinus tumor of Nasopharynx. Asean J clin Sci 1988; 8:33-5.
26. Malati T. Tumor Markers In Malignancies: The Role of Alphafetoprotein. Clin Proc NIMS 1989; 4:169-74.
27. Wang PY. Alphafetoprotein in non-hepatocellular malignant tumors. Chung-Hua Chun Liu Tsa Chih 1991; 13:61-3.
28. Morimoto H, Tanigawa N, Inoue H. Alphafetoprotein-producing renal cell carcinoma. Cancer1988, 61:84-8.
29. Brown JA, Roberts CS. Elevated serum alphafetoprotein levels in primary gall bladder carcinoma without hepatic involvement. Cancer 1992; 70:1838-40.
30. Keel BA, Harms RL, Leal JA. Characterisation of human alphafetoprotein charge microheterogeneity during the fetal development. 1990; 27:281-7.
31. Parmelec DC, Evanson MA, Deutsch HF. The presence of fatty acids in human alpha-fetoproteins. J Bio chem1978; 253:2114-9.
32. Smith CJ, Kelleher PC. Alphafetoprotein separation of two molecular variants by affinity chromatography with Concanavalin A agarose Biochem. Biophys Aeta 1973; 317:231-5.
33. Breborowicz J. Microheterogeneity of human alphafetoprotein: Tumor Biol 1988; 9:3-14.
34. Saraswathi A, Malati T. Clinical Relevance of Alphafetoprotein Microheterogeneity in Alphafetoprotein-Secreting tumors, Cancer Detection and Prevention 1994 ; 18:447-54.
35. Acevedo H F, Tong JY, Hartsock RJ. Human chorionic gonadotropin-beta subunit gene expression in cultured human fetal and cancer cells of different types and origins. Cancer 1995; 76:1467-75.
36. Marcillac I, Troalen F, Bidat JM. Free human chorionic gonadotrophin B subunit in gonadal and non-gonadal neoplasm. Cancer Res 1992; 52:3901-7.
37. Klee GG, Go VLW. Carcinoembryonic antigen and its role in clinical practice. In: Ghosh BG ed. Tumor associated antigens and other markers. New York: McGraw-Hill Inc1987; p: 23-43.
38. th Symposium on Tumor Markers, Hamburg 1986, George Thieme Verlag, Stuttgart New York, 1987; p:287-90.
39. Aabo K, Pedersen H, Kjaer M. Carcinoembryonic antigen (CEA) and alkaline phosphatase in progressive colorectal cancer with special reference to patient survival. Eur J Cancer Clin Oncol 1986; 22:211-7.
40. Wu JT, Knight JA, Knight DP. CEA in the clinical diagnosis and treatment of colorectal cancer. In: ACP Clinical Chemistry Check Sample. Chicago, III: American Society of Clinical Pathologists, 1986.
41. Terry WD, Henkart PA, Coligan JE. Carcinoembryonic antigen: characterization and clinical applications. Transplant Rev 1974; 20:100-129.
42. Rajani Kumari G, Malati T. Stability of total and free prostate specific antigen in serum samples at different storage conditions. Ind J Clin Biochem 2004; 19:10-13.
43. Malati T, Rajani Kumari G. Racial and ethnic variation of PSA in global population: Age specific reference intervals for serum prostate specific antigen in healthy south Indian males. Ind J Clin Biochem 2004; 19:132-7.
44. Saraswathi A, Malati T. A comparative study of tumor markers of adenocarcinoma prostate. Ind J clin Biochem 1995; 10:29-33.
45. Malati T, Rajani Kumari G, Murthy PVLN, Rammurthy S, Prayag A, Reddy R et al. The role of free and molecular complexes of PSA, TRUS and DRE and diagnosis and management of BPH and prostate carcinoma. In Proceedings of world congress of pathology and laboratory medicine, published by Medimond, 2003; pp79-88.
46. Malati T, Rajani Kumari G, Murthy PVLN, Rammurthy S, Ram Reddy Ch, Surya Prakash B. Prostate specific antigen in patients of benign prostate hypertrophy and carcinoma prostate. Ind J Clin Biochem 2006; 21:34-40.
47. Bast RC, Jr. Freeney M, Lazarus H, Nadler LM, Coloin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981; 68:1331-7.
48. O'Brien TJ, Raymond LM, Bannon GA. New monoclonal antibodies identify the glycoprotein carrying the CA 125 epitope. Amer J Obstet Gynecol 1991; 165:1857-64.
49. Davis HM, Zurawski VR, Bast RC, Jr. Klug TL. Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas. Cancer Research 1986; 46:6143-8.
50. Magnani J, Nilsson B, Brockhous M, Zopf D, Steplewski Z, Koprowski H, Ginsburg V. The Antigen of a Tumor Specific Monoclonal Antibody is a Ganglioside containing sialylated Lacto-N-Fucopentaose II, Federation Proceedings. 1982; 41:898.
51. Saraswathi A, Raghunadha Rao D, Malati T. Cancer Antigen 125 (CA 125) - A current marker for ovarian carcinoma. Current diagnostics, Clin Proc NIMS 1994; 9(2): 57-8.
52. Saraswathi A, Malati T. Superiority of CA 125 over CA 19-9 and CEA for epithelial ovarian malignancies. Ind J Clin Biochem 1996; 10:23-8.
53. Malati T, Rajani Kumari G, Yadagiri B. Application of tumor markers in ovarian malignancies. Ind J Clin Biochem 2001; 16:223-4.
54. Bast RC, Jr. Xu FJ, Yu YH, Zhang BH, Mills GB. CA 125: The past and the future . The Int J Biol Markers 1998; 13:179-87.
55. Rosenthal AN, Jacob IJ. The role of CA 125 in screening for ovarian cancer. The Int J Biol Markers 1998; 13:216-20.
56. Beck EP, Moldenhauer A, Merkle E, Kiesewetter F, Jager W, Wildt L, Lang N. CA 125 production and release by ovarian cancer cells. The Int J Biol Markers 1998; 13:200-6.
57. Meden H, Fattachi, Meibodi A. CA 125 in benign gynecological conditions. The Int J Biol Markers 1998; 13:231-7.
58. Pittaway DE. CA 125 in women with endometriosis. Obstet and Gynecol. Clinics North America 1989; 16:237-52.
59. Scharl A, Crombach G, Vierbuchen M, Muesch H, Bolty A. The use of CA 125 as a tumor marker for adenocarcinomas of endocervix, endometrium and fallopian tube. Tumor Diag Therapy1989; 10:17-20.
60. Goecze PM, Szabo DG, Than GN, Csaba IF, Krommer KF. Occurrence of CA 125 and CA 19-9 tumor associated antigens in sera of patients with gynecologic, trophoblastic and colorectal tumors. Gynecol Obstet Invest 1988; 25:268-72.
61. Shukla VK, Gurubachan, Sharma D, Dixit VK, Singh U. Diagnostic value of serum CA242, CA19-9, CA 15-3 and CA 125 in patients with carcinoma of the gall bladder 2006; 27:160-5.
62. Harmenberg U, Wahren B, Wiechel KL. Tumor markers carbohydrate antigens CA 19-9 and CA 50 and Carcinoembryonic antigen in pancreatic cancer and benign diseases of the pancreatobiliary tract. Cancer Res 1988; 48:1985-8.
63. Magnani J, Steplewski Z, Koprowski H, Ginsburg V. Identification of the Gastrointestinal and Pancreatic Cancer-Associated Antigen Detected by Monoclonal Antibody 19-9 in the Sera of patients as a mucin Cancer Research 1983, 43: 5489.
64. Malati T, Rajani Kumari G, Yadagiri B, Shantharam V, Ratnakar KS. Diagnostic utility of tumor markers in identification of unknown primary? Ind J Clin Biochem1996, 11:77-80.
65. Duffy MJ, Shering S, Sherry F, McDermott E, O'Higgins N. CA15.3: a prognostic marker in breast cancer. Int J Biol Markers 2000; 1:330-33.
66. Nalini R, Delphine W, Silvia CR, Makhija PM, Uthappa S. Usefulness of serum CA15.3 and Histopathological prognostic indices in breast cancer. Ind J Clin Biochem 2005; 20:165-8.
67. Thriveni K, Krishnamoorthy L, Ramaswamy G. Correlation study of carcino embryonic antigen & cancer antigen 15.3 in pretreated female breast cancer patient. Ind J Clin Biochem 2007; 22:57-60.
68. Ohuchi N, Takahashi K, Matoba N. Comparison of serum assays for TAG 72, CA 19-9, and CEA in gastrointestinal carcinoma patients. Jpn J Clin Oncol. 1989; 19:242-248.
69. Villena V, Lopez Encuentra A, Echave Sustaet J. Diagnostic value of CA 72-4, Carcinoembryonic antigen, CA 15-3, and CA 19-9 assay in pleural fluid. Cancer 1996; 78:736-40.
70. Holmgren J, Lindholm L, Persson B. Detection by monoclonal antibody of carbohydrate antigen CA 50 in serum of patients with carcinoma. Brit Med J 1984, 288, 1479-82.
71. Dnistrian AM, Schwartz MK, Greenberg EJ. CA 549 as a marker in breast cancer. Int J Biol Mark 1991; 6:139-43.
72. 2 Microglobulin: its significance and clinical usefulness. Ann Clin Lab Sci 1990; 29:163-8.
73. 2 microglobulin Lymphoproliferative and other neoplastic diseases of the central nervous system. Arch Neurol 1987; 44:915-20.
74. Gupta A, Malati T, Gupta PD. Differential Reduction in the expression of Keratin Polypeptides in human Gastric Carcinomas. Cancer Detection and Prevention 1997; 21:129-34.
75. Gupta A, Malati T, Gupta PD. Altered expression of keratin in epithelioid tumors. Current Science 1992; 62:288-93.
76. Gupta A, Malati T, Gupta PD. Intracellular proteins as tumor markers. Ind J Clin Biochem 1992, 7:81-8.
77. Bonfrer JMG, Gaarenstroom KN, Kenter GG. Prognostic significance of serum fragments of cytokeratin 19 measured by Cyfra 21-1 in cervical cancer. Gynecol Oncol 1994; 55:371-5.
78. Pujol JL, Grenier J, Daures JP. Serum fragment of cytokeratine subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Caner Res 1993; 53:61.
79. Weber K, Osborn M, Moll R. tissue polypeptide antigen (TPA) is related to the non-epidermal keratins 8, 18 and 19 typical of simple and non-squamous epithelia: re-evaluation of a human tumor marker. EMBO J 1984; 3:2707-11.
80. Kumar S, Costello CB, Glashan RW. The clinical significance of tissue polypeptide antigen (TPA) in the urine of bladder cancer patients. Br J Urol 1981; 53:578-82.
81. Austin LA, Heath H III. Calcitonin: Physiology and pathophysiology. N Engl J Med 1981; 304:269-78.
82. Smythe GA, Edwards G, Graham P. Biochemical diagnosis of Pheochromocytoma by simultaneous measurement of urinary excretion of Pheochromocytoma by simultaneous measurement of urinary excretion of epinephrine and nor epinephrine. Clin Chem 1992; 38:482-92.
83. Horn Y, Beal SL, Walach N. Further evidence for the use of polyamines as biochemical markers for malignant tumors. Cancer Res 1982; 42:3248-51.
84. Pogier H, Freis KG, Besse MG, et al. Two site immunoenzymometric assay of the 52 k da cathepsin D cytosols of breast cancer tissues. Clin Chem 1989; 35:81-5.
85. Tandon AK, Clark GM, Chamness GC, et al. Cathepsin D and prognosis in breast cancer. N Eng J Med 1990; 322:239-331.
86. O'Connor DT, Deftos LJ. Secretion of Chromogranin A by peptide producing endocrine neoplasms. N Engl J Med 1986; 314:1145-51.
87. Said JW, Vimadalal S, Nash G. Immunoreactive neuron specific enolase, bombesin and Chromogranin as markers for neuroendocrine lung tumors. Hum Pathol 1985; 1:236-40.
88. Harris AL, Nicholson S, Sainsbury JC. Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu. J Steroid Biochem 1989; 34:123-31.
89. Elledge RM, Ciocca DR, Langone G. Estrogen receptor, progesterone receptor, and HER 2/neu protein in breast cancers from pregnant patients. Cancer 1993; 71:2499-2506.
90. DeSombre ER, Hughes A, King WJ. Steroid receptors and breast cancer: current status and new applications for receptor directed diagnosis and therapy. Dev Oncol 1990; 58:155-69.
91. Kinoshita Y, Yamada S, Haraguichi K. Determination of vanillylmandilic acid, vanillactic aid, and homovanillic acid in dried urine on filter-paper discs by high performance liquid chromatography with colorimetric electrochemical detection for neuroblastomas screening. Clin Chem 1988; 34:2228-30.
92. Jorgensen LGM, Hirsch Fr, Skov BG, et al. Occurrence of neuron specific enolase in tumor tissue and serum in small cell lung cancer. Brit J Cancer. 1991; 63:151-3.
93. Schroy PC III, Brown shimmer S, Kim K. Detection of P21 ras mutations in colorectal adenomas and carcinomas by enzyme linked immunosorbent assay. Cancer. 1995; 76:201-9.
94. Harris CC, Hollstein M. Clinical implications of the P53 tumor suppressor gene. Engl J Med1993; 329:1312-8.
95. Angelopopulou K, Diamandis EP, Sutherland DJA. Prevalence of serum antibodies against the P53tumor suppressor gene protein in various cancers. Int J Can 1994; 58:480-7.
96. Easton DF, Bishop DT, Ford D. Breast Cancer Linkage Consortium, Breast and Ovarian cancer incidence in BRCA 1 mutation carriers. Am J Hum Genet 1995; 56:104-7.
97. Vogelstein B, Kinzler KW. Has the breast cancer gene been found? Cell 1994; 79:1-3.
98. Rio MC, Chambon P. The PS2 gene, mRNA, and protein: a potential marker for human breast cancer. Cancer Cells 1990; 2:269-74.
99. Molina R, Fillella X, Torres MD. SCC antigen measured in malignant and nonmalignant disease. Clin Chem 1990; 36:251-4
100. Malati T, Yadagiri B, Murali Mohan Krishna D, Shantaram V, Raghunadharao D, Subba Rao K. Spectrum of Monoclonal Gammapathies in Andhra Pradesh. Ind J Clin Biochem 2001; 16:52-9.
101. Malati T, Yadagiri B, Dinakar I, Sastry BDS, Subba Rao K. Unusual Monoclonal Gammapathies from South India. Trends Clin Biochem Lab Medicine 2003; p: 549-54.
102. Malati T, Jacob R, Singh AK, Subba Rao K. Paraproteinemia - A Review of Clinical, Biochemical and Radiological Aspects. Clin Proc NIMS 1988; 3:120-30.
103. Malati T. An overview of Monoclonal Gammapathies. Ind J Clin Biochem 2001;16:1-8.
104. Yadagiri B. Biochemical studies in Plasma Cell Malignancies with Predominant Osteoclastic Lesions of Bone. Ph.D. thesis, Osmania University, Hyderabad: 2004, pp 1-197.
105. Yilmaz G, Yilmaz FM, Senes M, Yucel D. Tumor marker requests in a general teaching Turkish Hospital. Ind J Clin Biochem 2007; 22:52-6.